share_log

Cantor Fitzgerald Initiates Coverage On Capricor Therapeutics With Overweight Rating, Announces Price Target of $8

Benzinga ·  Jan 5 10:31

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Capricor Therapeutics (NASDAQ:CAPR) with a Overweight rating and announces Price Target of $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment